Showing 1 to 5 of 5 results
Venizelos Alleges Novartis Conspiracy Against Greek Democracy
Former Greek vice-president Evangelos Venizelos testified in the Novartis trial on Thursday, alleging a conspiracy targeting political figures, including himself, to undermine democracy and the rule of law, criticizing the Parliament's actions and the Special Court's handling of the case.
Venizelos Alleges Novartis Conspiracy Against Greek Democracy
Former Greek vice-president Evangelos Venizelos testified in the Novartis trial on Thursday, alleging a conspiracy targeting political figures, including himself, to undermine democracy and the rule of law, criticizing the Parliament's actions and the Special Court's handling of the case.
Progress
44% Bias Score
Roche to Invest \$50 Billion in US Production
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in US production facilities over five years, creating 12,000 jobs, to mitigate trade war risks and strengthen its US market position, following a similar investment by Novartis.
Roche to Invest \$50 Billion in US Production
Roche, a Swiss pharmaceutical company, announced a \$50 billion investment in US production facilities over five years, creating 12,000 jobs, to mitigate trade war risks and strengthen its US market position, following a similar investment by Novartis.
Progress
32% Bias Score
Novartis Q4 Sales Beat Expectations Despite Full-Year Miss
Novartis reported better-than-expected Q4 2024 net sales of \$13.2 billion (16% increase), driven by Entresto and Cosentyx, exceeding analyst estimates but slightly missing its full-year sales forecast of \$50.47 billion; the company projects continued, albeit moderated, growth in 2025.
Novartis Q4 Sales Beat Expectations Despite Full-Year Miss
Novartis reported better-than-expected Q4 2024 net sales of \$13.2 billion (16% increase), driven by Entresto and Cosentyx, exceeding analyst estimates but slightly missing its full-year sales forecast of \$50.47 billion; the company projects continued, albeit moderated, growth in 2025.
Progress
24% Bias Score
Stournaras Testifies in Novartis Trial, Alleges Political Persecution
In the ongoing Novartis trial, Bank of Greece Governor Yannis Stournaras testified, alleging political motivations behind accusations against him and his wife, citing significant reductions in pharmaceutical spending during his time as finance minister and highlighting the extensive financial scruti...
Stournaras Testifies in Novartis Trial, Alleges Political Persecution
In the ongoing Novartis trial, Bank of Greece Governor Yannis Stournaras testified, alleging political motivations behind accusations against him and his wife, citing significant reductions in pharmaceutical spending during his time as finance minister and highlighting the extensive financial scruti...
Progress
72% Bias Score
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Novartis Reports Record 2024 Sales Despite Morphosys Write-Down
Novartis announced record 2024 financial results: \$50.3 billion in sales (up 11%), \$19.5 billion in operating core earnings (up 19%), and \$11.9 billion in net income (up 39%), driven by innovative medicines; however, a \$900 million write-down from the Morphosys acquisition impacted the results.
Progress
44% Bias Score
Showing 1 to 5 of 5 results